Issue link: https://www.e-digitaleditions.com/i/1507932
30 BioPharm International ® Emerging Therapies eBook September 2023 www.biopharminternational.com Supply Chain No company is an island "Despite the rise in highly engineered solutions, some- thing can always go wrong in the biologics cold chain, so the big question is what actions or interventions will need to be launched," says Schäpper. "Against this back- drop, it's more important than ever for pharma compa- nies to choose partners and service providers that have the experience and expertise to provide not only tech- nology solutions but a full range of services to intervene in the face of any event that could threaten the integrity of the biologic shipment." "To keep the sleepless nights to a minimum, life sci- ences companies must engage with their third-party logistics partners as early as possible in the commer- cialization process," says Coyle. "Understanding the specific needs of the biologic products and specific de- tails about the locations of the intended deliveries is critical to planning for the right equipment and plan- ning to reduce the risk of delay or disruption." Meanwhile, service providers are always working to line up strategic partners and acquisitions that can strengthen their overall capabilities. For exam- ple, over the past year or so, SpotSee, a manufacturer of environmental condition-monitoring solutions, has acquired both Marathon Products, a provider of temperature data loggers and monitors for ultra-low and high-temperature applications, and a portfolio of patented temperature-indicator technologies that can be integrated into packaging solutions, data log- gers, and monitors for the life sciences sector from Sensor International (3). In May 2023, CSafe, a provider of thermal shipping solutions for the biopharmaceutical cold chain, and Mo- dality Solutions, a cold chain engineering partner that has supported more than 80 drug approvals over the past three years, announced a strategic partnership to pro- vide a next-generation cold chain solution for CGTs (4). In August 2022, UPS Healthcare acquired multi-na- tional healthcare logistics provider Bomi Group, strengthening the company's global footprint by add- ing temperature-controlled facilities in 14 countries, and expands its scale and expertise across Europe and Latin America. "We're constantly looking at op- portunities for partnerships and are always building regional relationships, to strengthen our localized in- frastructures, because different customers all over the world have so many different needs," says Betancourt. References 1. Alliance for Regenerative Medicine. Sector Snapshot, April 2023: A New Vision. http://alliancerm.org/ w p-content/uploads/2023/04/ WEB_ A RM _ Sec- tor-Snapshot_Report_R02_Web.pdf 2. CSafe. CSafe Providing Sustainable Thermal Protec- tion for Vyjuvek Gene Therapy from Krystal Biotech. Press Release. May 22, 2023. 3. SpotSee. SpotSee Acquires Marathon Products. Press Release. May 8, 2023. 4. CSafe. Modality Solutions and CSafe Announce Stra- tegic Partnership to Provide Integrated, End-to-end Cold Chain Solution for Cell and Gene Therapies. Press Release. May 16, 2023. ■ Ajinomoto Bio-Pharma Services ........................................................................................................................................................................................................ 7 BioVectra DCL ..................................................................................................................................................................................................................................... 11 Bora Biologic .......................................................................................................................................................................................................................................21 Charles River Laboratories ................................................................................................................................................................................................................29 Curia ....................................................................................................................................................................................................................................................... 5 Distek.................................................................................................................................................................................................................................................... 19 Entegris ................................................................................................................................................................................................................................................27 Eurofins Lancaster Laboratories ........................................................................................................................................................................................................ 9 G-CON Manufacturing ....................................................................................................................................................................................................................... 15 Jubilant HollisterStier Contract Manufacturing ..............................................................................................................................................................................13 LabVantage Solutions, Inc. ................................................................................................................................................................................................................25 Sartorius Stedim North America, Inc ..............................................................................................................................................................................................31 Tosoh Bioscience ................................................................................................................................................................................................................................. 3 Ad Index COMPANY PAGE